Forte Biosciences (NASDAQ:FBRX – Get Free Report) had its target price hoisted by investment analysts at Chardan Capital from $3.00 to $64.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.
Forte Biosciences Stock Up 4.7 %
NASDAQ:FBRX opened at $5.84 on Friday. Forte Biosciences has a 52 week low of $4.11 and a 52 week high of $21.25. The stock’s fifty day moving average is $5.49 and its two-hundred day moving average is $2.31. The company has a market capitalization of $8.53 million, a P/E ratio of -0.32 and a beta of 0.04.
Forte Biosciences (NASDAQ:FBRX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). Sell-side analysts anticipate that Forte Biosciences will post -22.5 earnings per share for the current fiscal year.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Read More
- Five stocks we like better than Forte Biosciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Investing in Construction Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What Are Dividend Champions? How to Invest in the Champions
- Time to Load Up on Home Builders?
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
